BULIMIA NERVOSA TREATMENT MARKET ANALYSIS

Bulimia Nervosa Treatment MarketSize and Trends

The global bulimia nervosa treatment market is estimated to be valued at US$ 455.7 Mn in 2020, and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).

Figure 1: Global Bulimia Nervosa Treatment Market Share (%) Analysis, By Treatment Type, 2020

Increasing product launches for the treatment of mental illness among the population is expected to drive growth of the global bulimia nervosa treatment market over the forecast period.

Market players are indulged in product launches, which is expected to drive growth of the global bulimia nervosa treatment market over the forecast period. For instance, in 2019, Lupin Limited launched the generic version of antidepressant Fluoxetine tablets of strengths 10 mg and 20 mg in the U.S. market. Fluoxetine tablets are indicated for the treatment of bulimia nervosa, panic disorder, major depressive disorder, and others.

Increasing product approvals from the regulatory authorities is expected to fuel growth of the market over the forecast period.

Market players are engaged in receiving approvals from the regulatory authorities, which is an important step for launching the product in the market. For instance, on 9^th April 2020, Aurobindo Pharma received the U.S. Food and Drug Administration (U.S. FDA) approval for its generic anti-depressant Fluoxetine tablets, which will allow the manufacture and marketing of the Fluoxetine tablets of strengths 10 mg and 20 mg. The product is the generic version of Eli Lily and Company’s Prozac tablets.